

Altria

Product Stewardship Maximizes the Harm Reduction Potential of Potentially Reduced Risk Products (RRPs)

Donna Smith, Ph.D., DABT Altria Client Services LLC Richmond, VA 23219 Center for Research and Technology


74th Tobacco Science Research Conference Boston, MA

August 29 – September 1, 2021



Donna Smith | Regulatory Affairs | Altria Client Services | TSRC August 29 - 31, 2021 | #38

The Case for Product Standards for RRPs



Adult Smokers, who cannot or will not quit, should have access to acceptable RRP alternatives that are substantiated through science and evidence²

Altria

Science

- FDA should implement product standards under 907(a)(3) that facilitate the innovation of potentially RRPs and allow such products to enter the market more rapidly.
- Compliance with product standards may
 - Alleviate the amount of product-specific information required in a product application
 - Provide the basis for an abbreviated marketing authorization pathway for RRPs
 - Create industry-wide baselines for safety and quality

¹Based on ALCS analysis of PATH Wave 1 data Sept 12, 2013 – Dec 14, 2014. Response to question – "If a tobacco product made a claim that it was less harmful to health than other products, how likely would you be to use that product?" Numbers may not foot due to rounding.

²Press Release, FDA announces comprehensive regulatory plan to shift trajectory of tobacco-related disease, death (July 27, 2017), available at <u>https://www.fda.gov/news-events/press-announcements/fda-announces-comprehensive-regulatory-plan-shift-trajectory-tobacco-related-disease-death</u> ("Envision[] a world . . . where adults who still need or want nicotine could get it from alternative and less harmful sources. . .").

Donna Smith | Regulatory Affairs | Altria Client Services | TSRC August 29 - 31, 2021 | #38

EVALI – Absence of Product Stewardship

The Mysterious Vaping Illness That's 'Becoming an Epidemic'

A surge of severe lung ailments has baffled doctors and public health experts.

> https://www.nytimes.com/2019/08/31/health/vapingmarijuana-ecigarettes-sickness.htm

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin -Preliminary Report

https://doi.org/10.1056/NEJMoa1911614 Preliminary Report, Sep 6, 2019, Final Report Mar 5, 2020

HEALTH AND SCIENCE

Angelica LaVito

CANGELICALAVITO

Death toll climbs from vaping illnesses as Florida, Georgia report new fatalities

PUBLISHED WED, SEP 25 2019-4:05 PM EDT | UPDATED WED, SEP 25 2019-5:40 PM EDT Elijah Shama



A man vapes at a store on September 17, 2019 in New York City Spencer Platt | Getty Images

https://www.cnbc.com/2019/09/25/tenth-patient-dies-from-vaping-related-illness.htm


Centers for Disease Control and Prevention

- Vitamin E acetate is strongly linked to the EVALI outbreak. Vitamin E acetate has been found in product samples tested by FDA and state laboratories and in patient lung fluid samples tested by CDC from geographically diverse states. Vitamin E acetate has not been found in the lung fluid of people that do not have EVALI.
- Evidence is not sufficient to rule out the contribution of other chemicals of concern, including chemicals in either THC or non-THC products, in some of the reported EVALI cases.



Impact to Risk Perceptions

How did beliefs and perceptions about e-cigarettes change after national news coverage of the EVALI outbreak?



Perceived harm of e-cigarettes increased during a month of intense news coverage of EVALI



Adapted from Morgan JC, Silver N, Cappella JN (2021) How did beliefs and perceptions about e-cigarettes change after national news coverage of the EVALI outbreak? PLoS ONE 16(4): e0250908. <u>https://doi.org/10.1371/journal.pone.0250908</u>

"the act of minimizing the health, safety, environmental, and social impacts of a product and its packaging throughout all lifecycle stages, while also maximizing economic benefits."



https://www.productstewardship.us/page/Definitions


- Our product stewardship program focuses on the potential health impact – health and safety – to adult consumers independent of regulatory framework.
- We rely on core product stewardship principles that are practiced across the chemical, pharmaceutical, food and consumer packaged goods industries.



All product and company names are trademarks[™] or registered[®] trademarks of their respective holders. Use of them does not imply any affiliation with, endorsement by, or association of any kind between them and Altria Client Services.

Scientific Framework

Science



Product Stewardship Framework

- Robust processes to select and qualify product ingredients and materials
- Toxicological risk assessments of ingredients and constituents to minimize human health risks
- Pragmatic use of toxicological assays to assess the health impact of potentially reduced risk products



Data Requirements for all RRP categories

- Use only raw materials that are USP or food grade, if available
- Finished product recipe <u>full</u> ingredient disclosure
 - On a chemical specific level
- Exposure estimate daily use patterns of the finished product
- Physical and Mechanical Hazards Analysis
 - e.g., UL 8139

Altria

Science

Data on the stability of the product (as needed)





Toxicological Risk Assessment – Oral Products

- Select and qualify suppliers of USP/food grade materials that can provide sufficient documentation of purity/grade etc.
 - Ensures that each material contains the lowest levels of impurities/contaminants that are technically feasible and are in parallel with ingredients used in the food supply
 - Each ingredient should be generally recognized as safe (GRAS) for use in food
- Obtain FULL ingredient disclosure of the product.
 - This disclosure should be at the chemical level and, for almost all cases, each chemical should be identified with a CAS RN and a FEMA number (if applicable)
- Estimate daily consumption of the product

Altria

Science

 This data may be from actual use studies, in-market data or estimated from other sources Toxicology and Risk Assessment



Toxicological Risk Assessment - Oral Products

- Conduct an exposure assessment on each chemical entity and compare to acceptable daily exposure levels
 - Exposure levels should be are supported by the available data on which authoritative bodies (e.g., FDA, JECFA) made their GRAS determination, if available
 - Other comparisons may include the FEMA PADI, the threshold of toxicological concern (TTC), or derived values from toxicology studies
- Conduct risk assessments on any available constituent and stability data on compounds of interest

Toxicology and Risk Assessment



Guidance from EPA, OEHHA, TCEQ, ECHA, PQRI, etc.



EPA – US Environmental Protection Agency, OEHHA – The Office of Environmental Health Hazard Assessment (California Proposition 65), TCEQ – Texas Commission on Environmental Quality, ECHA – European Chemicals Agency, PQRI – Product Quality Research Institute

Toxicological Risk Assessment – Inhalable Products



- Selection of suppliers should have the same rigor as for oral products
 - All ingredients should be GRAS (if applicable) and food or USP grade
- Obtain FULL ingredient disclosure just as with oral products
- Estimate daily consumption of the product
- Conduct an exposure assessment on each chemical entity added to the e-liquid



Costigan S and Meredith C (2015) An approach to ingredient screening and toxicological risk assessment of flavors in e-liquids. Regulatory Toxicology and Pharmacology 72 https://doi.org/10.1016/j.yrtph.2015.05.018

Toxicological Risk Assessment – Inhalable Products



Science

- Route of exposure considerations are paramount
 - GRAS may not be sufficient
 - Product aerosols may contain different chemicals than those that were intentionally added to the formulation
- Consider the potential of leachates from any metal or plastic components (or other sources) in the liquid or aerosol stream
- Analyze the aerosol to determine chemical composition (e.g., HPHCs, leachates, etc.) and then perform risk assessment on each identified chemical entity
- Review available stability data and conduct risk assessments on compounds of interest

Risk Assessment Guides

 Threshold of Toxicological Concern (TTC) of 1.5µg/day – acceptable level for lifetime exposure to chemicals, including mutagens, via any route of exposure (ICH M7(R1))

D & DRUG				Q Matt
Produkta / Produkta Continenta Pro	operations / Marilet.anco	Reviewer Guides and Scientific Policy Memoranda about FDA Review of Tobacco Product Applications		
		Documents to help reviewers evaluate tobacco product applications. This information adds detail about FDA review processes and regulatory science issues.		
		4 ates 14 acts 19 rates 25 rate 24 acts		
Market an Tobacce P	nd Déstribute a Product	FDA's reviewer guides and science policy memoranda provide information about FDA review processes and several regulatory actions issues. These documents were developed to assist FDA reviewers with the valuation of anter behave product applications. FDA has	Central current as of: 15/25/2019	
Question	ot & Annuers	put these documents on this site in response to public interest, e.g. frequent Freedom of Information Art requests.	Regulated Product(s) Tobacco	
	el Tabacco Producto orive an INSE	Information contained in these documents is subject to change based on advances in policy, the regulatory framework, and regulatory science, and is not binding on FDA or the		
Telesco Orden	o Products Manketing	public. These documents offer a snapshot of FDA's thinking on certain aspects of tobacco regulatory science at the time the documents were written but do not necessarily represent		
	Dire Tobacco Depilcations Outs	FDA's complete or current thinking. These documents should not be used as a comprehensive manual for preparing or anticipating review of tobacco product applications.		
Spendic	r Guides and In Policy Membranda Di Besieve of Tobacco	General Unique Identification of Portioned Moist Smift and Snus Products 		

FDA U.S. FOOD & DRUG ADMINISTRATION MEMORANDUM To: File Digitally signed by Jonathan Fallica -5 Jonathan Fallica, PhD Date: 2019.03.11 19:33:43 -04'00' Division of Nonclinical Science, Office of Science Wanyoike Kang'ethe, PhD, Digitally signed by Wanyoikz W. Kangethe -5 ate: 2019.03.12 09:27:11 -04'00' Division of Nonclinical Science, Office of Science Zheng Tu, MD, PhD Digitally signed by Zheng Tu-S Division of Nonclinical Science, Office of Science Date: 2019.03.12 09:33:13 -04'00' Through: Susan Chemerynski, ScD, MPH Digitally signed by Susan Chemerynski -S Date: 2019.03.13 14:11:45 -04'00' Branch Chief, Division of Nonclinical Science, Office of Science Berran Yucesoy, MSc, PhD Digitally signed by Berran Yucesoy -S Branch Chief, Division of Nonclinical Science, Office of Science Date: 2019.03.14 11:54:58 -04'00' Hans Rosenfeldt, PhD Dicitally signed by Hans M. Rosenfeldt -5 Deputy Director, Division of Nonclinical Science, Office of Science Date: 2019.03.14 12:29:35 -04'00' Kimberly Benson, PhD Digitally signed by Kimberly A. Benson -5 Date: 2019.03.14 14:39:18 -04'00' Director, Division of Nonclinical Science, Office of Science Use of Reference Values in the Toxicological Evaluation of Inhaled Tobacco Products Subject: Purpose Different national and international agencies develop inhalation toxicity reference values to protect the health of the general population and occupational exposure levels or limits (OELs) to protect workers in occupational settings from harmful exposures. Substantial equivalence (SE) reports often cite these toxicity reference values and they are likely to be included in other regulatory applications [e.g., premarket tobacco product applications (PMTA) and modified risk tobacco product applications (MRTPA)]. This memorandum represents current thinking of the Division of Nonclinical Science (DNCS) on the use of toxicity reference values in evaluating inhalation exposure to constituents in tobacco smoke or aerosols. **Executive Summary** This memorandum provides an overview of the current thinking of DNCS in evaluating the use of toxicity reference values, including OELs, in tobacco product applications. All toxicity reference values for inhaled constituents should be evaluated on a case-by-case basis using the framework and approaches

outlined in this memorandum. DNCS concludes that for tobacco product applications, the selection and use of toxicity reference values for the general population should be consistent with the EPA tiering hierarchy (detailed in Section 4.1), which does not include OELs. With respect to OELs, DNCS will evaluate OELs that applicants use to support the levels of non-carcinogenic inhaled tobacco constituents.

Altria Science

https://www.fda.gov/tobacco-products/market-and-distribute-tobacco-product/reviewer-guides-and-scientific-policy-memoranda-about-fda-review-tobacco-product-applications


Donna Smith | Regulatory Affairs | Altria Client Services | TSRC August 29 - 31, 2021 | #38

Altria

Science


Toxicological Assays to Assess Potential Health Impact


- Ames reverse mutation assay (OECD 471)
- Neutral Red Uptake cytotoxicity assay (OECD 129/432)
- In vitro micronucleus assay (OECD 487)
- 90-day in vivo inhalation assay (OECD 413)




Negative

Positive






Adapted from Fenech et al, 2011 Mutagenesis, 26(1), 125.





Advancing FDA's Tox 21 Roadmap for Tobacco Products

- Ultimate goal of reducing, refining and replacing animal usage as well as regulatory acceptance of the findings
- Clinically relevant cell-based assays
- Computational dosimetry in vitro to in vivo extrapolation (IVIVE) to bolster the relevance to human health of in vitro findings





CORESTA 2021 – Smoke-Science (NAM Symposium)

DAY 2

TUESDAY 19 OCTOBER

SYMPOSIUM

Advancing New Alternative Methods (NAMs) for Tobacco Harm Reduction

Chair: K. Monica LEE Co-Chair: Shannon BELL

CET Time Zone		PART 1	
13:30-13:35	Welcome	COLARD S.	
		CORESTA, 11 rue du Quatre Septembre, 75002 Paris, France	
13:35-13:45	NAM 00	Advancing new alternative methods for tobacco harm reduction	
	Intro	LEE K.M.(1); BELL S.(2)	
		 Altria Client Services LLC, 601 East Jackson Street, Richmond, VA 23219, U.S.A. Integrated Laboratory Systems, 601 Keystone Park Drive, Suite 200, Morrisville, NC 27560, U.S.A. 	
13:45-14:10	NAM 01	US federal efforts to develop and implement alternatives to animal testing KLEINSTREUER N.	
		NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM), U.S.A.	
14:10-14:35	NAM 02	Application of biokinetic modelling for <i>in vitro</i> to <i>in vivo</i> extrapolation (IVIVE) in chemical risk assessment	
		PAINI A.; WORTH A.	
		European Commission Joint Research Centre (JRC), Ispra, Italy	
14:35-15:00	NAM 03	Inhalation exposure modeling for assessing health risks of toxic aerosols and vapors	
		CORLEY R.A.	
		Greek Creek Toxicokinetics Consulting (GCTC), LLC, Boise, ID 83714, U.S.A.	




Register at www.CORESTA.org



Scientific Framework

Science





- Product stewardship is paramount to the success of tobacco harm reduction
- These principles should be institutionalized into product standards
 - Create industry-wide baselines for safety and quality
 - Help industry and public health focus on the ultimate goal developing and authorizing products that move smokers to reduced risk products





Altria

Product Stewardship Maximizes the Harm Reduction Potential of Potentially Reduced Risk Products (RRPs)

Donna Smith, Ph.D. Altria Client Services LLC Richmond, VA 23219 Center for Research and Technology

74th Tobacco Science Research Conference Boston, MA

August 29 – September 1, 2021

